OEOsefanmen Matthew Enosolease

Osefanmen Matthew Enosolease

*This is an algorithmically generated author record based on publicly available information.

Osefanmen Matthew Enosolease has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Data Governance Challenges in Artificial Intelligence-Enabled Healthcare in Low- and Middle-Income Countries

    by Elona Erezi, Kehinde Jonathan Irhodia, Hussaini Abba Disa, Osefanmen Matthew Enosolease

    Background: Artificial intelligence (AI) has the potential to transform healthcare delivery in low- and middle-income countries (LMICs), where the disease burden from preventable causes is high and healthcare resources are severely limited. Although major technological breakthroughs have occurred, systemic, regulatory, and infrastructural barriers continue to hinder the implementation of AI-powered health solutions in these settings. Objectives: This review aims to examine and synthesise key data governance (DG) challenges and concerns in the context of health systems in LMICs, develop an analytical framework for assessing readiness to address data governance issues in AI-enabled health systems, and identify key areas for data governance policy interventions and future research. Methods: A structured narrative review of peer-reviewed literature from PubMed, Scopus, and Web of Science, together with relevant grey literature sources from January 2015 to December 2023, was conducted. AI governance, digital health infrastructure, digital health data regulation, and algorithmic accountability in LMICs were considered. Findings were analysed thematically to synthesise governance concerns across key governance dimensions. Results: Seven major governance challenge domains were identified: (1) weak and fragmented regulatory frameworks; (2) poor data quality and limited interoperability; (3) inadequate patient data protection mechanisms; (4) algorithmic bias due to undersampling of local populations; (5) inadequate digital health infrastructure; (6) limited digital literacy among healthcare professionals; and (7) ethical tensions related to consent, privacy, and community trust. Cross-cutting themes of power asymmetry in global AI development and donor dependency in digital health financing were also identified. Conclusions: The promise of AI for LMIC health systems needs to be supported by robust, place-sensitive governance structures that extend beyond technology alone. Before equitable AI adoption can be pursued, investments in regulatory capacity, data systems, algorithmic accountability mechanisms, and stakeholder engagement are critical preconditions. A Governance Readiness Framework is proposed to support policymakers, health ministries, and development partners.

  • Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review

    by Uchechukwu Bethel Abioke, Onyewuchi Onyinyechukwu Joy, Chinyere Elohor Egbordi, Osefanmen Matthew Enosolease

    Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.